<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6804">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03018340</url>
  </required_header>
  <id_info>
    <org_study_id>ACP-103-042</org_study_id>
    <nct_id>NCT03018340</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ACADIA Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ACADIA Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of pimavanserin compared to placebo when given adjunctively to a
      selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor
      (SNRI) antidepressant as treatment of patients with Major Depressive Disorder (MDD) and an
      inadequate response to antidepressant therapy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline to end of efficacy period in HAMD-17 total score</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Adjunctive Treatment of Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Pimavanserin 34 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug- pimavanserin, 34 mg, taken as two 17 mg tablets, once daily by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, taken as two tablets, once daily by mouth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimavanserin</intervention_name>
    <description>Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth</description>
    <arm_group_label>Pimavanserin 34 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, taken as two tablets, once daily by mouth</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients, aged 18 years and above

          2. A clinical diagnosis of major depressive disorder (MDD)

          3. Is being treated with one of the following SSRI or SNRI antidepressants as
             monotherapy:

               -  Citalopram

               -  Escitalopram

               -  Paroxetine

               -  Fluoxetine

               -  Sertraline

               -  Duloxetine

               -  Venlafaxine

               -  Desvenlafaxine

               -  Venlafaxine XR

          4. Has a history of inadequate response to antidepressant treatments

        Exclusion Criteria:

          1. Patient has a psychotic disorder other than MDD

          2. Patient has current evidence of a serious and/or unstable neurologic, cardiovascular,
             respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical
             disorder, including cancer or malignancies, which would affect the patient's ability
             to participate in the program

          3. Patient has a history or symptoms of long QT syndrome

        Patients will be evaluated at screening to ensure that all criteria for study
        participation are met. Patients may be excluded from the study based on these assessments
        (and specifically if it is determined that their baseline health and psychiatric condition
        do not meet all pre-specified entry criteria).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bryan Dirks, MD</last_name>
    <phone>609-250-6924</phone>
    <email>bdirks@acadia-pharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lori Jacobi</last_name>
    <phone>609-250-6901</phone>
    <email>ljacobi@acadia-pharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David P. Walling, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synergy San Diego</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed A. Bari, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard A. Hassman, DO</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 10, 2017</lastchanged_date>
  <firstreceived_date>January 10, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pimavanserin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
